Pfizer inSPIREd By Late-Stage PCSK9 Data
This article was originally published in Scrip
You may also be interested in...
Pfizer has decided not to move forward with an oral PCSK9 blocker in early clinical development because the efficacy wouldn’t stand up to injectable rivals.
Amgen’s PCSK9 blocker was cleared by FDA at a 420mg dose that can be administered once monthly via a hands-free device, offering a point of differentiation versus Sanofi/Regeneron’s Praluent.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.